Drugs / High-Dose IL-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03226236 | Mar 2016 → Mar 2019 | renal cell carcinoma | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | High-Dose IL-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03226236 ↗ |
| Route | Intravenous | “administered by continuous IV infusion” NCT03226236 ↗ |